Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talacotuzumab in HMA-Refractory MDS and AML
NCT02992860Phase 2Terminated
- Sponsor
- GWT-TUD
- Start
- Jul 2016
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of talacotuzumab in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by GWT-TUD. Started Jul 2016; status: terminated.
02
Drugs
talacotuzumab
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02992860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02992860.